The American Society of Nuclear Cardiology (ASNC) announced Feb. 27 that abstract submissions are now being taken for the upcoming ASNC 2014 meeting scheduled for Sept. 18-21 at the Seaport World Trade Center in Boston.

A treatment strategy for colon cancer combining molecular imaging, a radioimmunotherapy that seeks colon-specific anatomy and concomitant chemotherapy is being bundled as chemoradiotherapy to take out more metastatic disease, according to a study published online Feb. 20 in the Journal of Nuclear Medicine.

A reduction of the FDG maximum standardized uptake value is superior to visual analysis for the evaluation of treatment response in patients with Hodgkin's lymphoma, according to a study published online Feb. 24 in the Journal of Nuclear Medicine.

Varian Medical Systems out of Palo Alto, Calif., elected Andrew Eckert, 52, as head of the board of directors, the manufacturer of radiation oncology technology announced Feb. 20.

Patients who carry telltale genetic mutations are being targeted for expanded Parkinson’s research in a major study called the Parkinson’s Progression Markers Initiative, led by The Michael J. Fox Foundation, the advocacy group announced Feb. 25.

West Lafayette, Ind.-based biopharmaceutical company Endocyte announced Feb. 24 that the company's folate-receptor biomarkers vintafolide and etarfolatide had orphan drug status and were moving closer to approval with a review by the European Committee for Medicinal Products for Human Use (CHMP).

Piramal Imaging announced today that F-18 florbetaben, also known as NeuraCeq, is cleared for commercial marketing by the European Commission.

Not for another several months, the 2014 World Molecular Imaging Congress (WMIC) is scheduled to take Seoul, Korea, by storm from Sept. 17-20, but this week the Scientific Program Committee has made a formal request for abstracts to be submitted for presentation.